Emyria delivers more than $2 million in clinical billings in the past half-year
Emyria Ltd (ASX:EMD), a mental health and neurologically focused biotechnology company developing a cutting-edge MDMA-assisted therapy model, has had a busy...
Stay updated with breaking news from Pax Centre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Emyria Ltd (ASX:EMD), a mental health and neurologically focused biotechnology company developing a cutting-edge MDMA-assisted therapy model, has had a busy...
It’s been a difficult quarter for the biotech sector, with economies struggling to recover from high inflation making for a small appetite for risk. The ASX...
The cannabis industry has seen a significant surge in popularity in the last 10 years, leading to enhanced transparency, market understanding and growing...
The ASX 200 ended the day 0.8% lower with all sectors except utilities finishing in the red. The benchmark was dragged down by tech stocks as virtual...
Emyria Ltd (ASX:EMD) managing director Michael Winlo runs Proactive through the company’s September quarter highlights. EMD generated $1,034,172 of clinical...